Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q1 FY21 results · Apr–Jun 2020
Torrent Pharmaceuticals reported revenue from operations of ₹2,056.00 crore (up 1.7% from Q1 FY20) and net profit of ₹321.00 crore (up 48.6% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,056.00 | 2,022.00 | +1.7% | 1,946.00 | +5.7% |
| Other income | 4.00 | 20.00 | −80.0% | 15.00 | −73.3% |
| Total income | 2,060.00 | 2,042.00 | +0.9% | 1,961.00 | +5.0% |
| Profit before tax | 402.00 | 279.00 | +44.1% | 293.00 | +37.2% |
| Net profit for the period | 321.00 | 216.00 | +48.6% | 314.00 | +2.2% |
| EPS, basic (₹) | 18.98 | 12.74 | +49.0% | 18.56 | +2.3% |
| Net margin (%) | 15.6 | 10.7 | 16.1 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,727.00 | 1,603.00 | +7.7% | 1,491.00 | +15.8% |
| Other income | 7.00 | 31.00 | −77.4% | 21.00 | −66.7% |
| Total income | 1,734.00 | 1,634.00 | +6.1% | 1,512.00 | +14.7% |
| Profit before tax | 370.00 | 277.00 | +33.6% | 195.00 | +89.7% |
| Net profit for the period | 298.00 | 223.00 | +33.6% | 168.00 | +77.4% |
| EPS, basic (₹) | 17.63 | 13.18 | +33.8% | 9.91 | +77.9% |
| Net margin (%) | 17.3 | 13.9 | 11.3 |
Consolidated
- Filed with BSE
- 31 Jul 2020, 08:34 IST
- Board meeting
- 30 Jul 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jul 2020, 08:34 IST
- Board meeting
- 30 Jul 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Audited
- Source
- XBRL filing on BSE